Azathioprine/6-mercaptopurine metabolism in ulcerative colitis: A guide to metabolite assessment—an evidence-based approach

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing idiopathic inflammatory bowel disorders affecting over 1.7 million individuals in North America; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work- related productivity [1, 2]. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease (IBD) is to achieve and sustain a long- term disease remission with effective evidence-based corticosteroid-sparing therapeutic approaches that minimize the risk of drug-related toxicity.

Original languageEnglish (US)
Title of host publicationMedical Therapy of Ulcerative Colitis
PublisherSpringer New York
Pages145-152
Number of pages8
ISBN (Electronic)9781493916771
ISBN (Print)9781493916764
DOIs
StatePublished - Jan 1 2014

Keywords

  • 6-Mercaptopurine metabolism
  • Azathioprine
  • Evidence-based
  • Metabolite assessment
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Azathioprine/6-mercaptopurine metabolism in ulcerative colitis: A guide to metabolite assessment—an evidence-based approach'. Together they form a unique fingerprint.

Cite this